Skip to main content
SpringerLink
Log in

An Overview of the Status of Acellular Pertussis Vaccines in Practice

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Infection with Bordetella pertussis continues to result in widespread morbidity and mortality. Although whole cell pertussis vaccines are effective in controlling pertussis, concerns relating to adverse effects following vaccination have led to the development of a new generation of pertussis vaccines. Acellular pertussis vaccines have decreased endotoxin content and are less reactogenic than whole cell vaccines. The composition of acellular pertussis vaccines varies, resulting in differing immunogenicity. Recent studies have demonstrated that these vaccines, in general, have an efficacy similar to that of whole cell vaccines. The development of acellular pertussis vaccines is an advance that should result in less discomfort from vaccination and the potential for increased vaccine usage, resulting in the possible elimination of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States. Curr Probl Pediatr 1984; 14: 1–78

    PubMed  CAS  Google Scholar 

  2. Strebel P, Guris D, Tachdjian R, et al. Epidemiology of pertussis and the importance of laboratory diagnosis [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  3. Expanded Programme on Immunization. Global programme for vaccines and immunization: immunization policy. 1995: WHO Document WHO/EPI/GEN/95.3

  4. Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis 1992; 14: 708–19

    Article  PubMed  CAS  Google Scholar 

  5. Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464–71

    Article  PubMed  CAS  Google Scholar 

  6. Rosenthal S, Strebel P, Cassiday P, et al. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995; 171: 1650–2

    Article  PubMed  CAS  Google Scholar 

  7. Wright SW, Edwards KM, Decker MD, et al. Pertussis infection in adults with persistent cough. JAMA 1995; 273: 1044–6

    Article  PubMed  CAS  Google Scholar 

  8. Deen JL, Mink CM, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21: 1211–9

    Article  PubMed  CAS  Google Scholar 

  9. Mooi FR. Virulence factors of Bordetella pertussis. Antonie van Leeuwenhoek 1988; 54: 465–74

    Article  PubMed  CAS  Google Scholar 

  10. Tuonamen E, Weiss A. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory epithelial cells. J Infect Dis 1985; 152: 118–25

    Article  Google Scholar 

  11. Mortimer Jr EA. Pertussis vaccine. In: Plotkin SA, Mortimer Jr EA, editors. Vaccines. 2nd ed. Philadelphia: Saunders, 1994: 91–135

    Google Scholar 

  12. Tuomanen E, Weiss A, Rich R, et al. Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev Biol Stand 1985; 61: 197–204

    PubMed  CAS  Google Scholar 

  13. Winsnes R. Serological responses to pertussis. In: Wardlaw AC, Parton RD, editors. Pathogenesis and immunity in pertussis. New York: John Wiley and Sons, 1988: 283–307

    Google Scholar 

  14. Cody CF, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunization in infants and children. Pediatrics 1981; 68: 650–60

    PubMed  CAS  Google Scholar 

  15. Baraff LJ, Manclark CR, Cherry JD, et al. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8: 502–7

    Article  PubMed  CAS  Google Scholar 

  16. Blumberg DA, Lewis K, Mink CM, et al. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics 1993; 91: 1158–65

    PubMed  CAS  Google Scholar 

  17. American Academy of Pediatrics. Pertussis. In: Peter G, editor. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village (IL): American Academy of Pediatrics, 1994: 355–67

    Google Scholar 

  18. Cherry JD. Acellular pertussis vaccines — a solution to the pertussis problem. J Infect Dis 1993; 168: 21–4

    Article  PubMed  CAS  Google Scholar 

  19. Kimura M, Kuno-Saki H. Developments in pertussis immunisation in Japan. Lancet 1990; 2: 30–2

    Article  Google Scholar 

  20. Robinson A, Funnell SGP. Potency testing of acellular pertussis vaccines. Vaccine 1992; 10: 139–41

    Article  PubMed  CAS  Google Scholar 

  21. Shahin RD, Mink C, Wiedermann BL, et al. Laboratory correlates of protection and protective immunity to Bordetella pertussis. In: Ciardi JE, Mcghee JR, Keith J, editors. Genetically engineered vaccines: prospects for oral disease prevention. New York (NY): Plenum Publishers, 1992: 287–92

    Chapter  Google Scholar 

  22. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96 Suppl.: 548–57

    PubMed  CAS  Google Scholar 

  23. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96 Suppl.: 557–66

    PubMed  CAS  Google Scholar 

  24. Ad Hoc Group for the Study of Pertussis Vaccines. Placebocontrolled trial of two acellular pertussis vaccines in Sweden — protective efficacy and adverse events [published erratum appears in Lancet 1988; 1: 1238]. Lancet 1988; 1: 955–60

    Google Scholar 

  25. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334: 391–2

    Article  PubMed  CAS  Google Scholar 

  26. Gustafsson L, Hollander HO, Olin P, et al. A controlled trial of a two-component acellular and a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349–55

    Article  PubMed  CAS  Google Scholar 

  27. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N Engl J Med 1996; 334: 341–8

    Article  PubMed  CAS  Google Scholar 

  28. Simondon F. Senegal pertussis trial [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  29. Plotkin S, Cadoz M. An interpretation of the acellular vaccine trials [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  30. Trollfors B, Taranger J, Lagergard T, et al. A placebo controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333: 1045–50

    Article  PubMed  CAS  Google Scholar 

  31. Heininger U. Erlangen pertussis trial [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  32. Liese JG, Harzer E, Meschievitz CK, et al. Efficacy of BIKEN acellular pertussis vaccine combined with diphtheria-tetanus toxoids (Tripedia) in infants [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  33. Schmitt HJ, Zepp F, APV-050 Study Group. Immunogenicity, reactogenicity and protective efficacy of a three-component acellular pertussis (DTaP) vaccine in infants [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  34. Greco D, Salmaso S, Trial Working Group. The Italian trial on pertussis vaccine [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  35. WHO Meeting on Case Definition of Pertussis: 1991 Jan 10–11; Geneva. Geneva: World Health Organization, 1991: 4–5 (issue no. MIN/EPI/PERT/91.1)

  36. Centers for Disease Control. Food and Drug Administration approval of a second acellular pertussis vaccine for use among infants and young children. MMWR 1997; 46: 110–1

    Google Scholar 

  37. Centers for Disease Control. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus and pertussis vaccination series. MMWR 1996; 45: 676–7

    Google Scholar 

  38. Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J Infect Dis 1996; 173: 1256–9

    Article  PubMed  CAS  Google Scholar 

  39. Linneman CC, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975; 2: 540–3

    Article  Google Scholar 

  40. Edwards KM, Decker MD, Graham BS, et al. Adult immunization with acellular pertussis vaccine. JAMA 1993; 269: 53–6

    Article  PubMed  CAS  Google Scholar 

  41. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a booster dose of Hib conjugate vaccine in children with impaired immune responses following primary vaccination with DTaP-Hep B-PRP-T vaccine [abstract no. G61]. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996: 154

    Google Scholar 

  42. Meschievitz CK. Acellular DTP development at Pasteur Merieux-Connaught [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3–5; Washington, DC

  43. Centers for Disease Control. FDA approval of a Haemophilus b conjugate vaccine combined by reconstitution with an acellular pertussis vaccine. MMWR 1996; 45: 993–5

    Google Scholar 

  44. Greenberg DP, Wong VK, Partridge S, et al. Evaluation of a new combination vaccine that incorporates diphtheria-tetanusacellular pertussis (DTaP), hepatitis B (HB), and Haemophilus influenzae type b (Hib) conjugate (PRP-T) vaccines [abstract no. G70]. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: 170

    Google Scholar 

  45. Pichichero M, Passador S. Response to an Haemophilus influenzae B (HIB) Conjugate vaccine booster following low antibody responses to simultaneous DTaP-HIB-hepatitis B combination vaccine in infants [abstract no. 1076]. Presented at the Pediatric Academic Societies Annual Meeting: 1996 May 6–10; Washington, DC

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Infectious Diseases, University of the Philippines, Philippine General Hospital, Manila, Philippines

    Anna Lena Lopez

  2. Department of Paediatric Infectious Diseases, U.C. Davis Medical Center, 2516 Stockton Boulevard, Sacramento, California, 95817, USA

    Dean A. Blumberg

Authors
  1. Anna Lena Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean A. Blumberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean A. Blumberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lopez, A.L., Blumberg, D.A. An Overview of the Status of Acellular Pertussis Vaccines in Practice. Drugs 54, 189–196 (1997). https://doi.org/10.2165/00003495-199754020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199754020-00001

Keywords

Search

Navigation